GlassScriptPhysician profile
Kamal Amin
NPI 1265406516
$4,313.50
in general payments reported to CMS, 2019-2025
31 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $209 · 2021: $432 · 2022: $260 · 2023: $813 · 2024: $1,115 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,889 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,889.37 |
| Education | $142.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $599.61 | 2019-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $536.09 | 2019-2025 | Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $410.65 | 2024-2025 | |
| Travere Therapeutics, INC. | $335.08 | 2021-2025 | |
| Glaxosmithkline, LLC. | $289.05 | 2021-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $248.40 | 2023-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $155.65 | 2019-2023 | Korsuva, Veltassa |
| Ardelyx, INC. | $149.73 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $142.66 | 2022-2025 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $131.75 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $120.25 | 2022-2024 | Jynarque |
| Fresenius USA Marketing, INC. | $117.87 | 2019-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $114.69 | 2022-2025 | Tarpeyo |
| Bard Peripheral Vascular, INC. | $105.41 | 2020 | |
| Horizon Therapeutics Plc | $104.44 | 2023 | Krystexxa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $100.39 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $88.48 | 2025 | |
| Novo Nordisk INC | $84.98 | 2023-2025 | Ozempic, Wegovy, Rivfloza |
| Akebia Therapeutics INC | $73.37 | 2021-2025 | Vafseo |
| Daiichi Sankyo INC. | $54.19 | 2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.72 | 2024-2025 | Jardiance |
| Genzyme Corporation | $50.90 | 2025 | |
| Aurinia Pharma U.S., INC. | $39.80 | 2023 | Lupkynis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $35.77 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.93 | 2023 | Gattex |
| Kyowa Kirin, INC. | $28.47 | 2023 | Crysvita |
| Apellis Pharmaceuticals, INC. | $28.23 | 2025 | |
| Cycle Pharmaceuticals INC | $25.48 | 2025 | Venxxiva |
| Mallinckrodt Enterprises LLC | $21.11 | 2019 | |
| Lilly USA, LLC | $17.99 | 2024 | Jardiance |
| Lundbeck LLC | $15.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamal Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.